Fight Over Waze? Way
Health Care: Drugs
Galena Biopharma Inc (GALE: NASDAQ)
$2.56 -0.04 | -1.54%
05/24/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 6.58M | 9.25M | 8.75M | 8.63M |
| Research & Development | 14.61M | 11.54M | 7.87M | 8.89M |
| Operating Income before D & A (EBITDA) | -21.20M | -20.79M | -16.62M | -17.52M |
| Depreciation & Amortization | 49.00K | 163.00K | 172.00K | 162.00K |
| Interest Income | 0.00 | 30.00K | 5.00K | 0.00 |
| Other Income - Net | -13.14M | 9.27M | 4.63M | -862.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -34.39M | -11.65M | -12.16M | -18.54M |
| Interest Expense | 33.00K | 0.00 | 0.00 | 5.00K |
| Pre-Tax Income | -34.43M | -11.65M | -12.16M | -18.55M |
| Income Taxes | -1.05M | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -33.32M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | -1.64M | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -34.97M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -34.97M | -11.48M | -11.99M | -18.39M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-33.32M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -33.32M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.53 | -0.32 | -0.67 | -1.24 |
| Basic EPS from Discontinued Ops. | -0.03 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.56 | -0.32 | -0.67 | -1.24 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.56 | -0.32 | -0.67 | -1.24 |
| Basic Normalized Net Income/Share | -0.53 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.53 | -0.32 | -0.67 | -1.24 |
| EPS fr Discontinued Ops | -0.03 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.56 | -0.32 | -0.67 | -1.24 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.56 | -0.32 | -0.67 | -1.24 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.53 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with GALE
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
Latest GALE Headlines from TheStreet
- Galena Biopharma To Present At The 2013 Marcum MicroCap Conference 05.23.13 | 07:05 am
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results 05.09.13 | 04:05 pm
- Galena Biopharma Poster Presentation At The American Pain Society 32nd Annual Scientific Meeting 05.09.13 | 07:05 am
- William L. Ashton Joins Galena Biopharma's Board Of Directors 05.01.13 | 07:05 am
- Galena Biopharma To Present At The 12th Annual Needham Healthcare Conference 04.24.13 | 07:04 am
- Galena Biopharma To Present At The 2013 BIO International Convention 04.16.13 | 07:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- Galena Biopharma To Present At The 20th Annual Future Leaders In The Biotech Industry Conference 03.29.13 | 07:03 am
- 4 Stocks Under $10 Making Big Moves 03.26.13 | 02:03 pm
Press Releases for GALE
- Frost & Sullivan Applauds Galena Biopharma For Its Breakthrough Breast Cancer Vaccine, NeuVaxâ¿¢ - PR Newswire 03.12.13 | 07:03 am
- Galena Biopharma, Inc. Investor Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com - PR Newswire 06.12.12 | 09:06 am
- Galena Biopharma, Inc. To Webcast, Live, At RetailInvestorConferences.com On June 7th - PR Newswire 06.06.12 | 09:06 am
- RXi Pharmaceuticals’ Common Stock To Commence Trading Under The Symbol “RXII” - Business Wire 05.10.12 | 06:05 am
Partner Headlines for GALE
- Galena Biopharma: Will Developments Continue In 2013? - Seeking Alpha 04.03.13 | 09:04 am
- What Makes For A Market Leading Return In Biotechnology? - Seeking Alpha 01.22.13 | 09:01 am
- Galena Pulls Back While Analysts Rush To Its Defense - Seeking Alpha 12.17.12 | 08:12 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Morning Market Movers - Benzinga 12.04.12 | 09:12 am
- UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT - Benzinga 11.28.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- Are Galena Biopharma's Largest Shareholders Giddy About Their Drug Trial Results? - Wall St. Cheat Sheet 06.21.12 | 11:06 am
- Galena Biopharma Announces Public Offering of Common Stock - Benzinga 04.04.12 | 04:04 pm
